Risk-stratified DMARD tapering feasible in RA, reduces costs
Risk-stratified tapering of disease-modifying antirheumatic drug (DMARD) dosage using an algorithm appears to be feasible in patients with rheumatoid arthritis (RA) and reduces costs, according to findings of an analysis of the German RETRO study presented as an abstract at the 18th Annual Congress of the European League Against Rheumatism....
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 781, Seite 30 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Costs |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC199636846X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC199636846X | ||
| 003 | DE-627 | ||
| 005 | 20230516112754.0 | ||
| 007 | tu | ||
| 008 | 170901s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC199636846X | ||
| 035 | |a (DE-599)GBVOLC199636846X | ||
| 035 | |a (PRQ)proquest_journals_19265309950 | ||
| 035 | |a (KEY)0248955420170000000078100030riskstratifieddmardtaperingfeasibleinrareducescost | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a Risk-stratified DMARD tapering feasible in RA, reduces costs |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Risk-stratified tapering of disease-modifying antirheumatic drug (DMARD) dosage using an algorithm appears to be feasible in patients with rheumatoid arthritis (RA) and reduces costs, according to findings of an analysis of the German RETRO study presented as an abstract at the 18th Annual Congress of the European League Against Rheumatism... | ||
| 650 | 4 | |a Costs | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Rheumatism | |
| 650 | 4 | |a Health risk assessment | |
| 650 | 4 | |a Patients | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 781, Seite 30 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:781 |g pages:30 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1926530995 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 781 |h 30 | ||